Cite

HARVARD Citation

    Ng, M. et al. (2022). A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects. International journal of cancer. 151 (3), pp. 435-449. [Online]. 
  
Back to record